Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 25 of 27
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
NCT00421083
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
NCT00190736
A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
NCT00461786
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00190775
Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
NCT00190957
Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)
NCT00479726
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
NCT00088465
Duloxetine vs Placebo in the Treatment of General Anxiety
NCT00475969
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00103571
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
NCT00191750
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
NCT00087711
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00090012
Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
NCT00485875
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
NCT00190788
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
NCT00088010
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
NCT00088478
Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder
NCT00122824
Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response
NCT00191399
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
NCT00191451
Effects of Arzoxifene on Bone Mass and the Uterus
NCT00085956
Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
NCT00110370
A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer
NCT00190710
Olanzapine in Patients With Borderline Personality Disorder
NCT00091650
Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
NCT00191035
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder
NCT00088036
Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.
NCT00190905
Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy
NCT00485550
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
NCT00191464
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
NCT00207155
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
NCT00191672
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00071136
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
NCT00073411
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
NCT00485771
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
NCT00190931
A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg
NCT00382135
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00088049
A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction
NCT00381732
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191048
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
NCT00190749
Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease
NCT00191009
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00100776
Evaluation of Continuous Symptom Treatment of ADHD
NCT00486122
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT00063401
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
NCT00087698
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.
NCT00190814
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer
NCT00069875
Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes
NCT00191178
Study of FORTEO Use in Subjects in the Community Setting
NCT01078805
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
NCT00485407
To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections
NCT00547417
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.